fbpx
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • Gadgets & Electronics
    • Health & Bio
    • FinTech
    • IoT
    • Transportation & Logistics
    • Marketplaces & E-commerce
    • Ecosystem
    • Robotics
    • Investments
    • EdTech
    • Featured
  • Deals
    • Private Equity
    • Venture Capital
    • IPO & Markets
  • Interviews
    • Startup Investing
    • Fundraising
    • Product Launching
  • MORE
    • Events
    • Startups Advice
  • Submit an Article
  • REGISTER
  • login
No Result
View All Result
No Result
View All Result
Home Health & Bio

BioMe Inc. & Yonsei Medical Center sign technology transfer contract for pathbreaking microbiome treatment

AsiaTechDaily Writer by AsiaTechDaily Writer
30 December 2021
in Health & Bio
0
BioMe is working on microbe therapeutics.

BioMe is working on microbe therapeutics.

5
SHARES
Share on FacebookShare on Twitter
Bookmark(0)

Please login to bookmark

No account yet? Register

The microbiome treatment market is receiving global attention and is rapidly emerging as a new treatment alternative for various intractable diseases. However, recent clinical trial failure reports and the limitation to identify a clear mode of action demand a careful approach. Korea-based company BioMe Inc. wants to bring in disruption with pathbreaking microbiome-based therapeutics. 

Established in November 2020 by Professor Sang Sun Yoon of the Department of Microbiology and Immunology, Yonsei University College of Medicine, BioMe Inc. has been developing a microbiome-based live biotherapeutic product (LBP). Based on the distinguished microbiology research foundation of Yonsei University College of Medicine, BioMe Inc. 

(i) understands the bacteriological characteristics of the candidate strains, 

(ii) can prove its effectiveness using animal disease models, made possible in the state-of-the-art Avison Biomedical Research Centre.

To accelerate its research & development process, the startup recently signed a technology transfer contract with Yonsei University College of Medicine. BioMe Inc. would start developing microbiome-based therapeutics with the six patents transferred from Yonsei University College of Medicine.

The technology transfer under the contract includes a total of six patents, and BioMe’s development pipeline is as follows: 

No. Development Pipeline
1 A protein derived from airway microbiome with inhibitory effects against broad-spectrum respiratory infections
2 A microbiome-derived immune enhancing protein with clear anti-cancer effect
3 A skin microbiome showing efficacy in treating atopic dermatitis
4 A consortium of commensal microbes showing efficacy in treating inflammatory bowel disease
5 Novel synbiotics system inducing butyrate synthesis

In addition to the above technology, a novel pipeline capable of degrading TMA, a risk factor for cardiovascular disease, is under development by BioMe Inc.

Beyond discovering useful strains, BioMe Inc. is building a microbiome-based system that selectively produces beneficial metabolites or degrades hazardous counterparts. This development strategy represented by “Molecule First” is implemented through the iBTSTM (integrated BioMe Technology for Screen) platform.

Recently, Kim Bu Seon, a former managing director of SK Bioscience, has been recruited to design target product profiles for candidate strains. Preclinical trials are scheduled to begin in the first half of 2022, and clinical trials will begin in 2023.

What are your thoughts?
+1
1
Upvote
+1
0
Clap
+1
0
Clap
+1
0
On fire
+1
0
Meh
+1
0
Clap
+1
0
Previous Post

Indonesia’s Bukalapak names Willix Halim as interim CEO

Next Post

Singapore startup CyberHash raises $20m in Lemon-led funding

Related Posts

Biofourmis
Featured

Biofourmis hits unicorn status after $300m Series D funding

April 30, 2022
AyuHealth
Featured

India’s Ayu Health scores $27m in Series B funding

April 29, 2022
HealthBeats
Featured

Healthtech startup HealthBeats raises $3m to expand product in Australia, Singapore

April 28, 2022
Qure.ai
Featured

HealthTech startup Qure.ai raises $40 million in Series C funding round

March 30, 2022
Nalagenetics
Featured

Nalagenetics secures $12.6m in funding to boost genetic testing solutions

March 28, 2022
WISEYAK
Featured

Nepalese PE firm Team Ventures invests in AI healthtech startup WISEYAK

March 21, 2022
Next Post
CyberHash

Singapore startup CyberHash raises $20m in Lemon-led funding

Discussion about this post

No Result
View All Result

FREE NEWSLETTER

Copyright © 2021 AsiaTechDaily.com| About Us | Seed acceleratorTerms of Use| Privacy Policy| Cookie Policy Contact : [email protected] | DMCA.com Protection Status | trusted by Wimgo

No Result
View All Result
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • Gadgets & Electronics
    • Health & Bio
    • FinTech
    • IoT
    • Transportation & Logistics
    • Ecosystem
    • Marketplaces & E-commerce
    • Robotics
    • Investments
    • Featured
  • Deals
    • Private Equity
    • Venture Capital
    • IPO & Markets
  • Interviews
    • Startup Investing
    • Fundraising
    • Product Launching
  • MORE
    • Events
    • Startups Advice
  • Submit an Article
  • Forums
  • Jobs
  • REGISTER
  • Login

Copyright © 2021 AsiaTechDaily.com| About Us | Seed acceleratorTerms of Use| Privacy Policy| Cookie Policy Contact : [email protected] | DMCA.com Protection Status | trusted by Wimgo